The addition of CDK4/6 inhibitors to ET is efficacious in suppressing cell proliferation, delaying cancer progression and improving survival, and represents the current standard of care first-line therapy for advanced ER+/HER2-breast cancer. This evidence concerns the gene ERBB2 and breast cancer.